Download PDF
Exp Clin Endocrinol Diabetes 1988; 92(6): 252-256
DOI: 10.1055/s-0029-1210811
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Intranasal LH-RH Analogue Treatment of Precocious Puberty

Brygida Koehler1 , Maria Koehler2 , Rozalia Osuch-Jaczewska3
  • 1Pediatric Endocrinology Clinic (Head: B. Koehler), Silesian Academy of Medicine, Katowice, Poland
  • 2Pediatric and Haematology Clinic (Head: F. Sliwa), Silesian Academy of Medicine, Katowice, Poland
  • 3Neonatology Clinic (Head: R. Osuch-Jaczewska), Silesian Academy of Medicine, Katowice, Poland
Further Information

Publication History

1988

Publication Date:
16 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The agonistic analogues of luteinizing hormone releasing hormone were used in the treatment of precocious puberty (pp) in children. 12 children with pp were treated for 6 months with an intranasal LH-RH analogue (C6-C3-C2-naphtyl/D-alanine)-LHRH. The majority of the children had central precocious puberty. Only one child had peripheral pp. Laboratory assessment of estradiol, testosterone, LH and FSH levels revealed that 1000 μg/day of this analogue diminished the hormone levels only in the group of children with central and combined pp. Bone age, pelvic ultrasound examination, sexual development and growth rate were determined pre-, during and after the treatment. The growth velocity decreased and gonadal and sexual characteristic ceased advancing after the LH-RH therapy. Biochemical and hematological studies performed in our children did not show any significant changes during the treatment periods. No adverse effects were noted from the intranasal therapy. We conclude, that intranasal therapy is safe, convenient and effective in pp, but not of peripheral origin.

Key words

Precocious Puberty - Treatment - LH-RH analogue